Tags » Renal Cell Carcinoma

Cerulean Announces Fast Track Designation Granted for CRLX101 in Metastatic Renal Cell Carcinoma

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Cerulean Pharma Inc. (Nasdaq: CERU), a leader in Dynamic Tumor Targeting™, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Cerulean’s lead nanoparticle-drug conjugate, CRLX101, in combination with Avastin® (bevacizumab) for the treatment of metastatic renal cell carcinoma (mRCC) following progression through two or three prior lines of therapy. 499 more words

Regulatory

AVEO Names Keith S. Ehrlich as Chief Financial Officer

CAMBRIDGE, Mass.–(BUSINESS WIRE)–AVEO Oncology (NASDAQ:AVEO) today announced the appointment of Keith S. Ehrlich to the position of chief financial officer. In this role, Mr. 292 more words

Ovarian Cancer

Calithera Biosciences Announces Clinical Data Presentation at ASCO 2015

SOUTH SAN FRANCISCO, Calif., April 22, 2015 (GLOBE NEWSWIRE) — Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced that clinical data for its lead drug candidate CB-839, the Company’s novel, orally bioavailable glutaminase inhibitor, will be presented at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO), which is being held from May 29 to June 2, 2015 in Chicago, Illinois. 167 more words

Preclinical & Clinical

Cellceutix Provides Corporate Update

BEVERLY, MA–(Marketwired – April 21, 2015) – Cellceutix Corporation (OTC: CTIX) (the “Company”), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to provide shareholders with a comprehensive update on current corporate activity and pipeline development. 2,626 more words

Preclinical & Clinical

Calithera Biosciences Highlights Results From Six Preclinical Abstracts at the American Association for Cancer Research Annual Meeting 2015

SOUTH SAN FRANCISCO, Calif., April 21, 2015 (GLOBE NEWSWIRE) — Calithera Biosciences, Inc. (Nasdaq:CALA) a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today will announce preclinical data for its lead anti-cancer therapeutic candidate, CB-839, Calithera’s novel, orally bioavailable glutaminase inhibitor, at the American Association for Cancer Research, taking place April 18-22, 2015 in Philadelphia, Pennsylvania. 531 more words

Preclinical & Clinical

Argos Therapeutics Announces Publication of Data From Phase 2 Clinical Trial of AGS-003 Fully Personalized Immunotherapy for Treatment of Metastatic Renal Cell Carcinoma (mRCC)

DURHAM, N.C., April 21, 2015 (GLOBE NEWSWIRE) — Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced that data from a Phase 2 clinical trial of AGS-003, the company’s lead product candidate for the treatment of metastatic renal cell carcinoma (mRCC), have been published in the Journal for ImmunoTherapy of Cancer. 739 more words

Preclinical & Clinical

Biothera’s Imprime PGG Cancer Immunotherapy Drug Candidate Shows Potential to Enhance Efficacy of Immune Checkpoint Inhibitors

PHILADELPHIA–(BUSINESS WIRE)–A scientific poster presented today during a late-breaking session at the American Association for Cancer Research (AACR) annual meeting showed that Biothera’s Imprime PGG investigational cancer immunotherapy may have the potential to enhance the efficacy of anti-PD-1 and anti-PD-L1 immune checkpoint inhibitors. 516 more words

Preclinical & Clinical